| Today's Big NewsJun 26, 2023 |
| By Nick Paul Taylor Pfizer is dropping one of its oral obesity drug candidates after seeing elevated liver enzymes in clinical trials. The setback leaves the Big Pharma’s near-term prospects resting on a candidate that is given twice as often as rival weight loss medicines in development at Eli Lilly and Novo Nordisk. |
|
|
|
By Nick Paul Taylor Eli Lilly has laid down a marker in the race for the oral obesity market, linking its GLP-1 receptor agonist orforglipron to 14.7% weight loss at 36 weeks. The result sets a high efficacy bar for Pfizer but leaves ample room to improve on tolerability. |
By Angus Liu Despite the controversy surrounding a relationship with departing director Alex Denner, Susan Langer has secured enough investor support to join Biogen’s board. |
By Andrea Park Abbott unveiled a new partnership with the American Diabetes Association and kicked off its previously announced WeightWatchers collaboration during the ADA’s annual scientific sessions in San Diego on Saturday. |
|
Wednesday, July 12, 2023 | 2pm ET/11am PT In this webinar, we will explore how critical it is for life sciences companies to use data to analyze the behavior of cancer at the individual level, uncover new targets and biomarkers for precision therapies, and increase the value of existing oncology drugs to new indications. Register now.
|
|
By Annalee Armstrong Once heralded as a potential blockbuster, FibroGen’s pamrevlumab did not live up to expectations in a phase 3 study for a chronic lung disease. It’s the second time this month that the therapy missed the mark in a clinical trial, putting the San Francisco biotech into survival mode. |
By Max Bayer Erytech's merger with Pherecydes has reached the finish line after a contentious battle with an activist investor. The proposed merger was greenlighted by Erytech's shareholders, denying Akkadian Partners' request to reject it. |
By Nick Paul Taylor Next time a project hits a setback, think of Eversana Intouch’s Cannes gold lion winning campaign. The New York agency pivoted around a stumbling block that threatened to sink its campaign—and turned the hitch into a strength that bolstered its core message about the inequality of breast cancer care. |
By Andrea Park A range of study data presented by Medtronic at the American Diabetes Association’s annual scientific sessions over the weekend touts the benefits of its newly FDA-approved MiniMed 780G insulin pump technology for kids and teenagers. |
By Kevin Dunleavy The potential advantages of a daily-pill version of popular GLP-1 drugs for Type 2 diabetes and obesity are obvious compared to the weekly-injection routine most patients taking these drugs undergo. Last weekend at the American Diabetes Association Scientific Sessions in San Diego, market leaders Novo Nordisk and Eli Lilly presented data that showed their investigative oral GLP-1 treatments are making progress. |
By Gabrielle Masson Investor Blackstone Life Sciences is paying Sutro Biopharma $140 million cash and throwing in another potential $250 million in biobucks in exchange for royalties on possible future sales of Vaxcyte’s products. |
By Angus Liu Lundbeck CEO Deborah Dunsire is retiring on a high note in the neuroscience company’s history. After hitting the company's highest quarterly revenue in the first quarter, the five-year Lundbeck chief executive will pass the baton to UCB's neurology head. |
By Andrea Park Gelesis’ oral hydrogel technology was cleared by the FDA in 2019 based on clinical trials showing that it could help around 60% of users reduce their body weight by at least 5% over the course of six months—and a new study shows that the tech has largely maintained those results throughout its launch into real-world settings. |
By Fraiser Kansteiner To support production of VX-880 and a second clinical candidate for type 1 diabetes, VX-264, Vertex and Lonza are teaming up on process development and scale-up for the manufacturing of the drugmaker’s portfolio of stem cell-derived, fully differentiated insulin-producing islet cell therapies. |
By Andrea Park Conformis, a nearly two-decade-old maker of 3D-printed, personalized orthopedic implants, has agreed to be acquired by a competitor in the space: restor3d, a North Carolina startup that spun out of Duke University in 2017. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we discuss the most expensive drugs in the U.S., plus Eli Lilly's recent acquisition, the latest company to challenge the Inflation Reduction Act, and the rest of the week's headlines. |
|
|---|
|
|
|
Wednesday, July 12, 2023 | 11:00am ET / 8:00am PT Join us for this insightful discussion on how to unlock the full potential of liquid biopsy and be an integral part of the future of precision medicine. We’ll take a deep dive into the latest strategies and solutions designed to help overcome current challenges and empower researchers and clinicians with enhanced capabilities. Register now.
|
|
| WhitepaperLearn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperAutoantibody screening is promising for early cancer detection with the potential to improve the whole treatment decision tree, providing a less invasive, powerful approach. Sponsored by: Sengenics |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| eBookSee how clinical trial sponsors can build stronger strategies to address challenges across the patient enrollment funnel, starting with four necessary steps. Sponsored by: OneStudyTeam |
| WhitepaperThis paper outlines various market archetypes and key considerations leaders must address when prioritizing new potential markets for gene therapies. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| |
|
